These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32527494)

  • 1. Trypanocidal treatment of Chagas disease.
    Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Jun; ():. PubMed ID: 32527494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trypanocidal treatment of Chagas disease.
    Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Nov; 39(9):458-470. PubMed ID: 34736749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Approaches for the Treatment of Chagas Disease.
    Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
    Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease.
    Jackson Y; Wyssa B; Chappuis F
    J Antimicrob Chemother; 2020 Mar; 75(3):690-696. PubMed ID: 31754690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
    Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS
    Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems.
    Salomon CJ
    J Pharm Sci; 2012 Mar; 101(3):888-94. PubMed ID: 22161779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review.
    Arrúa EC; Seremeta KP; Bedogni GR; Okulik NB; Salomon CJ
    Acta Trop; 2019 Oct; 198():105080. PubMed ID: 31299283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
    Sulleiro E; Muñoz-Calderon A; Schijman AG
    Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in Chagas Disease Drug Discovery: A Review.
    Paucar R; Moreno-Viguri E; Pérez-Silanes S
    Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chagas Disease Chemotherapy: What Do We Know So Far?
    Zuma AA; de Souza W
    Curr Pharm Des; 2021; 27(38):3963-3995. PubMed ID: 33593251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease.
    Kratz JM; Garcia Bournissen F; Forsyth CJ; Sosa-Estani S
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):943-957. PubMed ID: 30111183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of Chagas disease chemotherapy.
    Guedes PM; Silva GK; Gutierrez FR; Silva JS
    Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.